Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexagene Holdings Inc LXXGQ

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Comment by Investor62on Mar 29, 2020 10:18am
86 Views
Post# 30857277

RE:RE:New 5 minutes test for COVID-19 by Abott

RE:RE:New 5 minutes test for COVID-19 by Abottwhy bad news? LXG main business is not testing the COVID-19. Don't forget what the main usage will be:
in their company presentation this is clearly shown. Main concentration is on the non-human medical tests:
Veterinary Diagnostics ~ $5.4B
Food Safety ~ $24.4B
Open-Access Use > $10B
This is a $40 billion market.
Clinical Diagnostics ($12.9B) requires FDA approval, and that's what they're working on. I don't think that a vaccine against the corona virus will have a negative or positive effect on their share price.
According to the last podcast Dr. Regan made it clear that the final completion (10%) will not be proprietary as commercialization is now the priority and the last 10% will be done "on the side". I expect that Q2, and Q3 will be very interesting, independent of the further development of the Corona virus, which in my opinion is not of great importance for LXG. 
<< Previous
Bullboard Posts
Next >>